Covid-19: sotrovimab monoclonal andtibodies
Ended Definitive Contract Awarded Last action
- Contract number
- W58P0522C0002
- Awardee
-
Glaxosmithkline, LLC UEI FRHTPHMZMX47
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $1,597,461,996
Award facts
- Contract value 56% obligated
-
- $1,597,461,996.00 Current, with exercised options
- $2,853,184,716.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $560,000 | |
| Supplemental Agreement for work within scope | $700,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $945,107,496 | |
| Original award | $651,094,500 |
About this award
This is a $2,853,184,716.00 COVID-19 contract awarded by the Joint Program Executive Office for Chemical, Biological, Defensive (JPEO-CBD) to Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company. The contract is for the procurement of Sotrovimab monoclonal antibodies, an antiviral medication used to treat COVID-19. The contract does not have a set-aside designation.
The prime contractor, Glaxosmithkline, LLC, has a history of federal contract awards and grants, primarily focused on supplying influenza vaccines and other pharmaceutical products to various government agencies, including the Departments of Justice, Veterans Affairs, Defense, Health and Human Services, and State. For this contract, Glaxosmithkline, LLC has a sub-contractor, ASD Specialty Healthcare, LLC (doing business as Amerisourcebergen), which will provide distribution services for the Sotrovimab procurement.
Quick answers
Who was awarded contract W58P0522C0002?
W58P0522C0002 was awarded to Glaxosmithkline, LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on November 15, 2021.
How much is contract W58P0522C0002 worth?
The government has obligated $1,597,461,996 on W58P0522C0002. Its potential value, with all options, is $2,853,184,716.
Which agency awarded contract W58P0522C0002?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W58P0522C0002, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W58P0522C0002 competed?
The extent of competition for W58P0522C0002 was full and open competition after exclusion of sources. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award